Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco DB Oil Fund (DBO) vs Novavax Inc (NVAX) Price & Performance

Invesco DB Oil FundTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Invesco DB Oil Fund vs Novavax Inc — how do they compare? Invesco DB Oil Fund trades at $24.14 (market cap $255.13M), while Novavax Inc trades at $11.92 (market cap $1.82B). The key difference: Novavax Inc is far larger — about 7.1× Invesco DB Oil Fund's market cap, and Invesco DB Oil Fund is more actively traded (562,167 versus 6,198,505). Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Oil Fund for 31 Days and Novavax Inc for 59 Days on average.

DBONVAX
Market Cap
$255.13M$1.82B
Volume
562,1676,198,505
Sector
Commodities - EnergyHealth
52-Week High
$26.35$12.56
52-Week Low
$11.98$6.22
Typical Hold Time
31 Days59 Days
Enterprise Value
—$1.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco DB Oil Fund

DBO trades at $23.54, down 0.42% on the day, with technical indicators showing a neutral to bearish bias. The stock faces resistance at $24 and support at $23, while moving averages signal bearish momentum. Recent oil market developments, including Middle East tensions and OPEC+ production decisions, create a volatile backdrop for energy stocks.

The outlook remains cautious given geopolitical risks and mixed oil price signals. Investment opportunities exist if supply disruptions persist, but risks include potential price declines from strategic reserve releases and ongoing legal challenges facing the oil industry.

Novavax Inc

Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.

The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DBO
0% Buy100% Sell
Avg holding period · 31 Days
NVAX
59% Buy41% Sell
Avg holding period · 59 Days

Top news

Latest headlines on both assets

About Invesco DB Oil Fund

DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.

Read more on DBO →

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX →